Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis
View Full Paper
Ask AI
Bookmark
Share
Key result
Andexanet alfa increased hemostatic effectiveness (85.8% vs 68.1%, OR 2.73) and reduced 30-day mortality (7.9% vs 19.6%, OR 0.36) compared to 4F-PCC in patients with FXa inhibitor-associated ICH.
Why the study?
Although andexanet alfa is approved as a specific reversal agent for factor Xa inhibitors and 4F-PCC is commonly used off-label, evidence directly comparing their effectiveness and safety in apixaban- or rivaroxaban-associated intracranial hemorrhage was needed.
Does andexanet alfa improve hemostatic effectiveness and reduce mortality compared to 4F-PCC in adults with apixaban- or rivaroxaban-associated intracranial hemorrhage?
Comparison
Andexanet alfa vs 4F-PCC
Design
Two-cohort comparison study with propensity score-overlap weighted analysis
Follow-up
30 days
Authors
Discussion
Loading...
Member takes
Implication
Supports consideration of andexanet alfa for FXa inhibitor ICH reversal; hypothesis-generating pending randomized confirmation.
Study Design
Type
Cohort (n=202)
Multicenter
Yes
Structured PICO
Does andexanet alfa improve hemostatic effectiveness and reduce mortality compared to 4F-PCC in adults with apixaban- or rivaroxaban-associated intracranial hemorrhage?
P
Population
202 adults with apixaban- or rivaroxaban-associated intracranial hemorrhage, followed for 30 days.
E
Exposure
Andexanet alfa (96.6% received low dose)
C
Comparator
Four-factor prothrombin complex concentrate (4F-PCC) (79.3% received a 25 unit/kg dose)
O
Outcome
Hemostatic effectiveness from index to repeat scansurrogate
Main Result
Odds Ratio: 2.73 (95% CI 1.16–6.42)
Absolute Event Rate: 85.8% vs 68.1%
In patients with apixaban- or rivaroxaban-associated intracranial hemorrhage, andexanet alfa was associated with improved hemostatic effectiveness and lower 30-day mortality compared to 4F-PCC.
Limitations
- No data on incidence of early do not resuscitate orders (DNR) or withdrawal of life-sustaining therapy
- Thrombotic events only reported for the first five days after reversal administration, and EHR data for 4F-PCC made identification less reliable
- Findings most applicable to patients with baseline GCS scores >= 8 and hematoma volumes <= 60 mL managed in the USA
- Risk of residual confounding due to unobserved or unmeasured covariates inherent to observational designs
- Anti-FXa assays were not available in most 4F-PCC patients to assess baseline anticoagulation levels
- Small sample size limited the ability to perform robust subgroup and sensitivity analyses
Cite This Study
Costa et al. (2022) conducted a cohort in Apixaban- or rivaroxaban-associated intracranial hemorrhage (n=202). Andexanet alfa vs. Four-factor prothrombin complex concentrate (4F-PCC) was evaluated on Hemostatic effectiveness (excellent/good) (OR 2.73, 95% CI 1.16-6.42). Andexanet alfa increased hemostatic effectiveness (85.8% vs 68.1%, OR 2.73) and reduced 30-day mortality (7.9% vs 19.6%, OR 0.36) compared to 4F-PCC in patients with FXa inhibitor-associated ICH.
Topics
View Full Paper
Ask AI
Bookmark
Share